H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Deciphera Pharmaceuticals (NASDAQ:DCPH) on Wednesday, setting a price target of $70, which is approximately 137.13% above the present share price of $29.52.
Fein expects Deciphera Pharmaceuticals to post earnings per share (EPS) of -$1.06 for the third quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Deciphera Pharmaceuticals, with an average price target of $65.
The analysts price targets range from a high of $70 to a low of $60.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $25.16 million and a net profit of -$61.49 million. The company's market cap is $1.71 billion.
According to TipRanks.com, H.C. Wainwright analyst Andrew Fein is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 15.0% and a 46.38% success rate.
Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. The company designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.